Medical Executive (1-year contract)

At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections,  where you are valued, accepted and respected for who you are, allowing you to thrive both personally and professionally. This is how we aim to prevent, stop and cure diseases and ensure everyone has access to healthcare today and for generations to come. Join Roche, where every voice matters.

The Position

Division: Medical Affairs, Affiliate / Local Market

Reporting line: Medical Function / Country Medical Director

The Opportunity:

The Medical Partner is a trusted, externally focused, scientifically grounded partner within our customer engagement model. By building and maintaining deep and trusted connections with key customers over a meaningful period of time, the Medical Partner will generate impact by anticipating and proactively optimizing medical practice, and ensure that Roche is a preferred partner in our key disease areas. 

The Medical function serves as a critical engine of competitiveness to ensure our innovations reach their full potential for patients with an end to end perspective. The role of the Medical Partner is designed to maximize local and cross-country medical and scientific activities to accelerate the delivery of our pipeline, differentiate our portfolio based on data, drive strategic advocacy, community engagement, medical practice adoption, and access to our portfolio by proactively capitalizing on "Moments that Matter" across the asset lifecycle.

As the Medical Executive, you are responsible for:

A. Contributing with Medical Expertise (core & common):

• Medical Expertise: responsible for proactively contributing strong scientific, medical, and therapeutic area expertise within the relevant diseases informing differentiation of our pipeline and portfolio. Acting as a medical expert for the pipeline and portfolio throughout the product life cycle.

• Shape Strategy: Lead the medical part of the integrated strategy, shape a scientifically sound and differentiated value story locally and communicate Roche’s contributions across key disease areas, reflecting an end-to-end business perspective that pulls through the strategy with impact.

B. Proactive Customer Engagement & Insights (core & common):

• Proactive Targeted Medical Engagement: As a medical function our ambition is to spend the majority of our time proactively engaging with external customers as partners in the integrated customer engagement strategy. The Medical Partner serves as the scientific and medical expert, proactively engaging TAEs, and other key stakeholders in full strategic and operational alignment with other in-field roles (ie. PJP, GMCL, HSP).  In the pre-launch phase it is the priority to drive proactive E2E strategies that deliver superior experience, anticipate the future and shape medical practice accordingly. In the post-launch phase the engagement continues to ensure that the right patients are treated at the right time and the engagement scope expands on unserved patient populations. In-field engagement serves as a critical component of this overarching strategy for targeted scientific engagement. It is understood that based on business needs the Medical Partner can serve as the primary point of contact for certain customers with the ambition to drive required healthcare system changes and where feasible earlier and broader adoption of our transformative portfolio.

Medical Partnership & Education: Establish and maintain effective peer-to-peer relationships with external stakeholders and identify/develop science-driven collaborations with TAEs. 

Provide current, high-quality Medical Education and differentiating scientific information to external customers, support the scientific training of internal teams and ensure continuous education on medical knowledge for PPoC roles. Conduct high-quality, non-promotional Scientific Exchanges to disseminate relevant data, foster physician confidence and clinical endorsement based on differentiating evidence and experience.

• Insight Generation: Based on aligned goals in the Squad, the Medical Partner should systematically collect, analyze, and translate external scientific and clinical practice insights (including patient perspectives) into strategic actionable and differentiating recommendations for the Squad. Insights are secured in peer to peer discussions and via targeted medical activities. One of the medical activities involves the execution of medical/scientific advisory boards as a source of insights and strategic counsel. 

C. License to operate & Operational Excellence (core & common):

• Adherence to Standards: Ensure all medical activities, including customer engagements, research projects, and material co-creation, are executed in line with company policies, procedures, and the highest compliance standards. This includes strict adherence to corporate policies, ethical behaviour,  local regulatory requirements as well as Good Clinical Practice (GCP), Good Pharmacovigilance Practice (GVP).

Additional Modules (to be adopted if applicable & adapted per local guidance)

D. Evidence Generation (Module Evidence Generation):

• Integrated Evidence Planning: Develop the local integrated evidence plan (IEP), including a comprehensive local evidence gap analysis of required value narratives for the diverse set of healthcare system stakeholders, patients and caregivers. This analysis is crucial to  inform global and cross-country opportunities and identify remaining requirements for local evidence to support medical practice adoption, access and continuous value demonstration across the asset life cycle. Strategic decision making, portfolio prioritization and resource allocation is to follow accordingly. 

• Evidence Strategy Implementation: Contribute directly to the local evidence strategy, proactively identifying local differentiating evidence gaps, and facilitating the development and implementation of differentiating tactics to address the prioritized gaps, specifically to ensure, maintain and broaden access to our portfolio. 

These differentiating tactics include supporting Non-Interventional Studies (NIS), externally submitted Investigator-Initiated Studies (IIS) with a relevant strategic fit, and Real-World Evidence/Data (RWE/RWD) studies, scientific projects and other activities.

• Clinical Development Support: Collaborate closely with Clinical Operations (PDG) and Legal/Regulatory (LEG) teams to provide support for Phase I-IV clinical studies when needed. This includes partnering with PDG for site engagement such as proactive input on feasibility and strategic site selection, participating in selected SIVs providing essential medical expertise and relevant knowledge to aid in study execution in collaboration with GMCL (Global Medical Collaboration Leader) and / or other functions as applicable per local agreement. For selected sites (global most valuable customers) take an active role in the OneRoche (g/pRED, PD, GPS, Affiliate, PT, Diagnostics) E2E holistic customer experience loop. Ensure that key insights from investigators, study coordinators and nurses are brought into the strategic planning of “how to go to market” and the local IEP gap analysis.

E. Focusing on Patient Impact and driving the value story in the HTA process (Module HTA):

• Maximizing HTA Value: Contribute scientific and medical expertise to local Health Technology Assessment (HTA) submissions and interactions, ensuring critical appraisal mindset on our data packages with good statistical understanding and by discussing the evidence for its transferability to the real-world healthcare setting. The medical partner will support market access to articulate the differentiating value story of our innovations in the local context to secure patient access. 

• The medical partner ensures early insights are used to generate local IEP/local gap analysis so data generation initiatives support the HTA value package locally.

The medical partner validates the data's scientific integrity and, through additional stakeholder exchange (TAEs/societies), ensures the HTA submission is clinically relevant and credible.

• Shaping Medical Practice: In parallel with the development of strategic partnerships with external customers to shape medical practice and drive the adoption of medical innovations, a core focus of the role is the systematic collection of insights, as well as the identification and addressing of medical and customer needs. These insights will serve to inform and guide the development or localization of the Disease Area (DA) company’s strategy. This includes contextualizing AI information with internal and external stakeholders as new technologies will disrupt the role of medical professionals.

• Fast access to innovative medicines: Enable broader impact on underserved patients by integrating medical perspectives into solutions that support the entire patient journey.

F.  Pipeline Product Strategic Contribution / Shaping (Module Pipeline):

• Providing insight and recommended actions linking to the highest value propositions (VP’s) for the affiliate pipeline products and/or new indications.</